Cervical cancer prevention: Immunization and screening 2015

Medical Clinics of North America

Volumn 99, Issue 3, 2015, Pages 469-477

  Thaxton, Lauren ^a   Waxman, Alan G ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Cervical cancer screening; Cytology; HPV vaccine; Human papillomavirus

Indexed keywords

WART VIRUS VACCINE;

CANCER GRADING; CANCER PREVENTION; CANCER SCREENING; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS TYPE 4; HYSTERECTOMY; IMMUNIZATION; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SCREENING TEST; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; WART VIRUS; FEMALE; IMMUNOLOGY; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

FEMALE; HUMANS; IMMUNIZATION; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 84926215667     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2015.01.003     Document Type: Review

References (44)

1. American Cancer Society Cancer facts and figures 2014 2014, American Cancer Society, Atlanta (GA).
2. Sawaya G.F., Grimes D.A. New technologies in cervical cytology screening: a word of caution. Obstet Gynecol 1999, 94(2):307-310.
3. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. JPathol 1999, 189:12-19.
4. Forman D., de Martel C., Lacey C., et al. Global burden of human papillomavirus and related diseases. Vaccine 2012, 30S:F12-F23.
5. Munoz N., Bosch F.X., de Sanjosé S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. NEngl J Med 2003, 348:518-527.
6. Serrano B., Alemany L., Tous S., et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012, 7(1):38.
7. Garland S.M., Hernandez-Avila M., Wheeler C.M., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. NEngl J Med 2007, 356:1928-1943.
8. The FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. NEngl J Med 2007, 356:1915-1927.
9. Paavonen J., Naud P., Salmerón J., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(9686):301-314.
10. Centers for Disease Control and Prevention (CDC) FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010, 59(20):626-629. [Erratum in MMWR Morb Mortal Wkly Rep 2010;59:1184].
11. Centers for Disease Control and Prevention (CDC) Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011, 60(50):1705-1708.
12. Papanicolaou G.N., Traut H.F. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol 1941, 42:193-206.
13. Waxman A.G. Guidelines for cervical cancer screening: history and rationale. Clin Obstet Gynecol 2005, 48(1):77-97.
14. Cuzick J., Clavel C., Petry K.U., et al. Overview of the European and North American studies on HPV testing in primary cervical screening. Int J Cancer 2006, 119:1095-1101.
15. McRory D.C., Batcher D.B., Bastian L., et al. Evaluation of cervical cytology: evidence report/technology assessment no.5 1999, Agency for Healthcare Policy and Research, Rockville (MD), AHCPR Publication no. 99-E010.1115.
16. Mayrand M.H., Duarte-Franco E., Mansour N., et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. NEngl J Med 2007, 357:1579-1588.
17. Stoler M.H., Schiffman M., Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001, 285:1500-1505.
18. Katki H.A., Kinney W.K., Fetterman B., et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011, 12:663-672.
19. Sherman M.E., Lorincz A.T., Scott D.R., et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. JNatl Cancer Inst 2003, 95(1):46-52.
20. Dillner J., Rebolj M., Birembaut P., et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008, 337:a1754.
21. Castle P.E., Cremer M. Human papillomavirus testing in cervical cancer screening. Obstet Gynecol Clin North Am 2013, 40:377-390.
22. Ronco G., Dillner J., Elfstrom K.M., et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomized controlled trials. Lancet 2014, 383:524-532.
23. Smith H.O., Tiffany M.F., Qualls C.R., et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study. Gynecol Oncol 2000, 78(2):97-105.
24. Herzog T.J., Monk B.J. Reducing the burden of glandular carcinomas of the uterine cervix. Am J Obstet Gynecol 2007, 197(6):566-571.
25. Katki H.A., Schiffman M., Castle P.E., et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. JLow Genit Tract Dis 2013, 17(5):S28-S35.
26. Wright T.C., Stoler M.H., Sharma A., et al. Evaluation of HPV-16 and HPV-18 genotyping for the triage women with high-risk HPV+ cytology negative results. Am J Clin Pathol 2011, 136:578-586.
27. Moyer V.A., U.S.Preventive Services Task Force Screening for cervical cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2012, 156(12):880-891.
28. Saslow D., Solomon D., Lawson H.W., et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. JLow Genit Tract Dis 2012, 16(3):175-204.
29. Committee on Practice Bulletins-Gynecology Screening for cervical cancer. Practice Bulletin 131. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012, 120:1222-1238.
30. Winer R.L., Lee S., Hughes J.P., et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003, 157:218-226.
31. Howlader N., Noone A.M., Krapcho M., et al. SEER cancer statistics review, 1975-2011 2014, National Cancer Institute, Bethesda (MD), Available at:, based on November 2013 SEER data submission, posted to the SEER web site. http://seer.cancer.gov/csr/1975_2011/.
32. Ho G.Y., Bierman R., Beardsley L., et al. The natural history of cervical papillomavirus infection in young women. NEngl J Med 1998, 338:423-428.
33. Kulasingam S., Havrilesky L., Ghebre R., et al. Screening for cervical cancer: a decision analysis for the US Preventive Services Task Force 2011, Agency for Healthcare Research and Quality, Rockville (MD), AHRQ Pub. No. 11-05157-EF1.
34. Schiffman M., Wentzensen N. From human papillomavirus to cervical cancer. Obstet Gynecol 2010, 116(1):177-185.
35. Dunne E.F., Unger E.R., Sternberg M., et al. Prevalence of HPV infection among females in the United States. JAMA 2007, 297:813-819.
36. Gyllensten U., Gustavsson I., Lindell M., et al. Primary high-risk HPV screening for cervical cancer in post-menopausal women. Gynecol Oncol 2012, 125:343-345.
37. Rodriguez A.C., Schiffman M., Herrero R., et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. JNatl Cancer Inst 2008, 100:513-517.
38. Sawaya G.F., Grady D., Kerlikowske K., et al. The positive predictive value of cervical smears in previously screened postmenopausal women: the Heart and Estrogen/progestin Replacement Study (HERS). Ann Intern Med 2000, 133:942-950.
39. Wu X., Matanoski G., Chen V.W., et al. Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States. Cancer 2008, 113(Suppl 10):2873-2882.
40. Pearce K.F., Haefner H.K., Sarwar S.F., et al. Cytopathological findings on vaginal Papanicolaou smears after hysterectomy for benign gynecologic disease. NEngl J Med 1996, 335:1559-1562.
41. Melnikow J., McGahan C., Sawaya G.F., et al. Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. JNatl Cancer Inst 2009, 101(10):721-728.
42. Stokley S., Jeyarajah J., Yankey D., et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013 and postlicensure vaccine safety monitoring, 2006-2014-United States. MMWR Morb Mortal Wkly Rep 2014, 63:620-624.
43. Harrison C., Britt H., Garland S. Decreased management of genital warts in young women in Australian general practice post introduction of National HPV Vaccination Program: results from a nationally representative cross-sectional general practice study. PLoS One 2014, 9(9):e105967.
44. Brotherton J.M., Fridman M., May C.L., et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377(9783):2085-2092.